Detalles de la búsqueda
1.
Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
World J Urol
; 39(7): 2635-2643, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33337513
2.
Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms.
Br J Clin Pharmacol
; 87(7): 2777-2789, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33247951
3.
Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
World J Urol
; 38(2): 463-472, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31079189
4.
Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms.
Br J Clin Pharmacol
; 86(8): 1585-1599, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32144791
5.
Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo-controlled study.
Int J Clin Pract
; 74(5): e13480, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31927774
6.
Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study.
Int J Clin Pract
; 73(9): 1-9, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30317693
7.
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
BJU Int
; 121(4): 647-658, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29044968
8.
Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.
Int J Urol
; 25(11): 944-951, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30198102
9.
Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
Prostate
; 77(16): 1573-1582, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28971497
10.
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
World J Urol
; 35(3): 421-427, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27334136
11.
Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.
Int J Clin Pract
; 70(10): 870-880, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27774780
12.
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
BJU Int
; 116(3): 450-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25565364
13.
Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.
World J Urol
; 32(5): 1141-7, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24903347
14.
Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
World J Urol
; 32(5): 1133-40, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24804842
15.
NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro.
Antibiotics (Basel)
; 13(4)2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38666984
16.
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.
J Urol
; 189(3): 871-7, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23021996
17.
Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
Eur Urol Focus
; 9(1): 178-187, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35985933
18.
Evaluation of a 3-item screening tool to identify men with benign prostatic enlargement/obstruction in a primary care cohort.
Minerva Urol Nephrol
; 74(1): 85-92, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32993275
19.
Computer recognition of cancer in the urinary bladder using optical coherence tomography and texture analysis.
J Biomed Opt
; 13(2): 024003, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465966
20.
Relative Bioavailability of Fixed-Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers.
Clin Pharmacol Drug Dev
; 7(4): 422-434, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28800206